
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
The Ishikawa cell line was established from an endometrial adenocarcinoma of a 39-year-old female patient. This human endometrial cancer model exhibits tumorigenic properties, forming well-differentiated adenocarcinomas in athymic nude mice. Ishikawa cells express estrogen and progesterone receptors both in vitro and in induced tumors, and they respond to steroid hormone stimulation. The cells have also been reported to produce corticotropin-releasing hormone, placental alkaline phosphatase, and chorionic gonadotropin. Ishikawa is widely used as a model for studying endometrial cancer biology, hormone receptor signaling, reproductive endocrinology, and endocrine-based therapeutic research.
Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 2
Reference Transcript: NM_014867
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use






Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?